Swiss pharma giant Novartis announces layoffs
Novartis, the Swiss pharmaceutical giant, has announced plans to streamline operations by cutting up to 680 jobs in its development organization, with around 440 positions in Switzerland and up to 240 roles in the United States affected over the next few years. This decision aligns with a broader restructuring program aiming to potentially cut 8,000 jobs globally, reflecting trends seen across the industry. Competitors like Roche have also implemented similar measures, with Novartis focusing on optimizing efficiency amid evolving market dynamics.
Despite the reductions, Novartis reaffirms its commitment to innovation in both Switzerland and the United States, intending to reshape its capabilities and access local talent, particularly in regions like Britain. The spokesperson highlighted Switzerland’s role as an innovation hub for complex development projects, while emphasizing the United States’ significance as a key development center.
